MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

Search

ADMA Biologics Inc

Închisă

SectorSănătate

21.36 8.98

Rezumat

Modificarea prețului

24h

Curent

Minim

19.6

Maxim

21.4

Indicatori cheie

By Trading Economics

Venit

76M

112M

Vânzări

-2.3M

118M

P/E

Medie Sector

27.346

59.668

EPS

0.136

Marjă de profit

95.191

Angajați

685

EBITDA

-2.7M

40M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+16.88% upside

Dividende

By Dow Jones

Următoarele câștiguri

8 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.4B

5.3B

Deschiderea anterioară

12.38

Închiderea anterioară

21.36

Sentimentul știrilor

By Acuity

50%

50%

172 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

ADMA Biologics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 apr. 2025, 22:00 UTC

Achiziții, Fuziuni, Preluări

Union Says Nippon Steel Can't Be Trusted With Buying U.S. Steel

22 apr. 2025, 20:55 UTC

Câștiguri

Intuitive Surgical Reports Higher 1Q Profit, Warns of Tariff Hit to Margins

22 apr. 2025, 23:49 UTC

Market Talk

Nikkei May Rise After Wall Street Rally -- Market Talk

22 apr. 2025, 23:49 UTC

Market Talk

Gold Falls on Signs of Easing U.S.-China Tensions, Possible Profit-Taking -- Market Talk

22 apr. 2025, 23:47 UTC

Top știri

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 4th Update

22 apr. 2025, 23:08 UTC

Achiziții, Fuziuni, Preluări

Woodside: No Change to Annual Guidance

22 apr. 2025, 23:07 UTC

Achiziții, Fuziuni, Preluări

Woodside: Assessing Impacts of Recent Tariff Announcements on Louisiana LNG

22 apr. 2025, 23:07 UTC

Achiziții, Fuziuni, Preluări

Woodside: Advancing Talks Targeting Further Equity Selldown in Louisiana LNG

22 apr. 2025, 23:06 UTC

Achiziții, Fuziuni, Preluări

Woodside: Trion Project 26% Complete, on Track for First Oil in 2028

22 apr. 2025, 23:05 UTC

Achiziții, Fuziuni, Preluări

Woodside: Scarborough Energy Project on Track for First LNG Cargo in 2H 2026

22 apr. 2025, 23:05 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy: Scarborough Energy Project 82% Complete

22 apr. 2025, 23:05 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy: Beaumont New Ammonia Project on Track to Start in 2H

22 apr. 2025, 23:05 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy: Beaumont New Ammonia Project 90% Complete

22 apr. 2025, 23:04 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy: Share of Sangomar Production Maintained at 78 Million Bbl/Day in 1Q

22 apr. 2025, 23:04 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Macquarie Set for A$500 Million Gain on Sale From Nomura Deal -- Market Talk

22 apr. 2025, 23:04 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy Sold 25.4% of Produced LNG at Prices Linked to Gas Hub Indices in 1Q

22 apr. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy Cites Lower Output, Reduced Oil-Linked Prices for Revenue Fall

22 apr. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy 1Q Revenue Down 5% on Prior Quarter

22 apr. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy 1Q Revenue US$3.315 Billion

22 apr. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

Woodside Cites Weather Impacts at North West Shelf, Pluto Unplanned Outages in 1Q

22 apr. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy 1Q Oil, Natural Gas Output Down 4% on Prior Quarter

22 apr. 2025, 23:01 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy 1Q Oil, Natural Gas Output 49.1 Million BOE

22 apr. 2025, 22:31 UTC

Câștiguri

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- Update

22 apr. 2025, 22:26 UTC

Top știri

Trump Is Laying the Groundwork to Blame Powell for Any Downturn -- Update

22 apr. 2025, 22:16 UTC

Top știri

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 3rd Update

22 apr. 2025, 22:16 UTC

Market Talk

Turkey Remains on Course for Steadily Lower Inflation, Finance Minister Says -- Market Talk

22 apr. 2025, 22:04 UTC

Top știri

China Tariffs 'Won't Be Anywhere Near' 145%: Trump -- Barrons.com

22 apr. 2025, 21:42 UTC

Câștiguri

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- WSJ

22 apr. 2025, 21:21 UTC

Top știri
Câștiguri

Tesla Profit Sinks, Hurt by Political Backlash -- 3rd Update

22 apr. 2025, 21:19 UTC

Top știri

Investors Hope for No Surprises as Boeing Reports Earnings -- Barrons.com

Comparație

Modificare preț

ADMA Biologics Inc Așteptări

Obiectiv de preț

By TipRanks

16.88% sus

Prognoză pe 12 luni

Medie 25 USD  16.88%

Maxim 25 USD

Minim 25 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruADMA Biologics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

19.66 / 21.5899Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

172 / 382 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.